NR5A1 and kidney disorder: In extensive preclinical testing, the therapeutic potential of the ELP–VEGF fusion protein was demonstrated for treatment of kidney disease, including renal artery stenosis-induced renovascular disease [36,46,47] and chronic kidney disease [48].